Inhibition of glycolysis or the Akt pathway has been shown to sensitize GC cells to 5-fluorouracil (5-Fu), highlighting potential therapeutic targets for overcoming resistance in both in vitro and in vivo models [52]. The gene discussed is AKT1; the disease is gastric cancer.